Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
Open Access
- 2 January 2015
- journal article
- Published by Informa UK Limited in OncoImmunology
- Vol. 4 (1), e954829
- https://doi.org/10.4161/21624011.2014.954829
Abstract
Myeloid-derived suppressor cells (MDSCs) contribute to tumor-mediated immune escape and negatively correlate with overall survival of cancer patients. Nowadays, a variety of methods to target MDSCs are being investigated. Based on the intervention stage of MDSCs, namely development, expansion and activation, function and turnover, these methods can be divided into: (I) prevention or differentiation to mature cells, (II) blockade of MDSC expansion and activation, (III) inhibition of MDSC suppressive activity or (IV) depletion of intratumoral MDSCs. This review describes effective mono- or multimodal-therapies that target MDSCs for the benefit of cancer treatment.Keywords
This publication has 80 references indexed in Scilit:
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- Emerging Tim-3 functions in antimicrobial and tumor immunityTrends in Immunology, 2011
- Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functionsInternational Immunopharmacology, 2011
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyInternational Journal of Cancer, 2011
- Sunitinib facilitates the activation and recruitment of therapeutic anti‐tumor immunity in concert with specific vaccinationInternational Journal of Cancer, 2010
- Therapeutic targeting of myeloid-derived suppressor cellsCurrent Opinion in Pharmacology, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- HIF-Dependent Antitumorigenic Effect of Antioxidants In VivoCancer Cell, 2007
- Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancerNature Medicine, 2007